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INTRODUCTION 
Novel coronavirus 2019 (nCoV-2019) are cover, positive-
sense single-stranded RNA viruses with a nucleocapsid 
of helical symmetry. Viruses that cause the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) have 
widely been known to cause respiratory and intestinal 
infections in humans after the outbreak of “severe acute 
respiratory syndrome” or SARS, also known as 
Coronavirus disease or COVID-19 (Zumla et al., 2016; Cui 
et al., 2019; Li et al., 2020). The causative coronavirus of this 
outbreak was named SARS-CoV-2 due to its 
resemblance to SARS-CoV. The SARS-CoV-2 infects 
ciliated bronchial epithelial cells and type-II 
pneumocytes via angiotensin-converting enzyme 2 
(ACE2) as a receptor, while MERS infects unconditional 
bronchial epithelial cells and type-II pneumocytes using 
dipeptidyl peptidase 4 (DPP4) also known as CD26 as a 
receptor (Zhang et al., 2020; Rockx et al., 2020). 
The mechanism related to the SARS-CoV-2 infection is 
still unclear. However, structural analysis shows the 
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 Abstract 
At the end of December 2019, a novel coronavirus was identified 
which caused severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) with a disease known as coronavirus disease 2019 
(COVID-19). The virus first originated in the city of Wuhan in China, 
causing symptoms such as pneumonic plague, which began in the 
Wuhan region and then spread throughout the world with high 
transmission efficiency. Special precautions and care are needed such 
as leaving the public area, covering your mouth with a mask, not 
shaking hands, washing hands, and sanitation from time to time. 
Infection due to SARS-CoV-2 shows several symptoms, one of which 
is very often the patient shows difficulty breathing. Currently, 
COVID-19 has been declared a global pandemic and has almost 
attacked all countries in the world, including in India which has one 
of the largest human populations in the entire world. One of the 
challenges in handling COVID-19 is the unavailability of drugs or 
special vaccines to treat the disease, so clinical practitioners and 
academics are currently testing various drugs to see how they affect 
the COVID-19 patients. Some of the drugs tested provide effective 
mechanisms against SARS-CoV-2, such as chloroquine, remdesivir, 
lopinavir, and vaccines under development, showing efficacy to 
inhibit SARS-CoV-2 infection in vitro. These drugs are still being 
tested and are now at the forefront to combat the effects of SARS-CoV-
2 infection. This review article will discuss all kinds of ins and outs of 
SARS-CoV-2 and COVID-19, including the transmission method, how 
to prevent it, as well as various drugs and vaccines currently used in 
handling COVID-19. 
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possibility of the virus entering human cells through 
several pathways, one of which is ACE2 receptors (Zhou 
et al., 2020; Astuti & Ysrafil, 2020). This newly emerged 
virus has much more similarity with SARS-CoV than 
MERS-CoV, thus both SARS-CoV and SARS-CoV-2 may 
cause pathogenesis through similar mechanisms 
transmission of SARS-CoV to humans (Xu et al., 2020; 
Khan et al., 2020a). Due to this COVID-19 all over the 
world face pandemic conditions (Khan et al., 2020b). 
This review article will discuss all kinds of ins and outs of 
SARS-CoV-2 and COVID-19, including the transmission 
method, how to prevent it, as well as various drugs and 
vaccines currently used in handling COVID-19. Also, this 
article discusses the statistical impact of COVID-19 on 
several countries, especially in India. This article also 
discusses information regarding the handling of COVID-
19 specifically in India, including the inspection location 
of SARS-CoV-2 samples that are spread throughout all 
regions of India. It is hoped that this review article will 
provide actual information regarding the current 
condition of the impact of COVID-19 and the therapies 
that are being developed to handle it. 
 
STRUCTURE AND PROTEIN FUNCTION 
In general, the structure and function of proteins from 
SARS-CoV-2 have similarities with other coronavirus 
families such as SARS-CoV and MERS-CoV although 
SARS-CoV-2 was found to infect more human beings 
than either of its predecessors (Pal et al., 2020). There are 
five main proteins in SARS-CoV-2 that play an important 
role related to the nature of pathogens in humans, 
consisting of the nucleocapsid (N), spike (S), viral 
envelope (E), and membrane protein (M), as well as 
hemagglutinin esterase (HgE) (Walls et al., 2020). The 
function of each protein is presented in Table I, while the 
structural illustration of SARS-CoV-2 as reported by 
Khan et al. (2020b) is presented in Figure 1. 
Table I. Structure and protein function of SARS-CoV-2 
Structural Protein Function of Protein 
Nucleocapsid Protein 
(N) 
N-Bound to RNA genome to 
make up nucleocapsid 
Spike Protein  
(S) 
S-Critical for binding of host cell 
receptors to facilitate entry of 
host cell 
Viral Envelope Protein 
(E) 
E-Interacts with M to form the 
viral envelope 
Membrane Protein (M) M-Central organizer of CoV 
assembly 
M-Determines shape of the viral 
envelope 
Hemagglutinin esterase  
(HgE) 
It is a glycoprotein that 
certain enfold viruses possess, it 
is used as invading function  
Source: Wang et al. (2020a); Seah et al. (2020) 
 
 
Figure 1. The structure of SARS-CoV-2 (Khan et al., 2020b) 
 
SYMPTOMS, PREVENTION, AND MODE 
OF TRANSMISSION 
Symptoms of COVID-19 
In general, COVID-19 can affect anyone, young or old, 
male or female, in all parts of the world. However, the 
symptoms shown between individuals are not always 
the same (Yi et al., 2020). Some individuals with certain 
conditions show a tendency for more severe symptoms 
and need treatment in hospitals, while some people do 
not cause clinical symptoms at all. This disease also 
causes more symptoms in the elderly and people with 
special underlying health conditions such as the presence 
of certain congenital diseases (Singhal, 2020). However, 
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most people infected with COVID-19 experience the 
following symptoms: 
1. Fever 
2. Common cold 
3. Cough 
4. Sore throat 
5. Fatigue 
6. Shortness of breath 
7. Running nose (Wang et al., 2020b). 
Prevention of COVID-19 infection 
The SARS-CoV-2 is known to be transmitted directly 
from human to human. At this point, the best way to 
prevent the spread of COVID-19 is to minimize direct 
contact with other humans (Yuen et al., 2020). Some ways 
can be done, including avoiding traveling outside the 
house or to public places if there is no urgent need, taking 
a safe distance of several meters with others if forced to 
interact, and increasing the body's immune system by 
routinely exercising and consuming various vitamins 
(Ali & Alharbi, 2020). The following are some precautions 
that can be taken to prevent or minimize the spread of 
COVID-19, including: 
1. Wash your hands thoroughly with soap and water 
for at least 20 seconds. 
2. Avoiding touching the nose, mouth, eyes, or other 
parts of the face except after washing hands or using 
a hand sanitizer. 
3. Use hand sanitizers that contain antiseptics such as 
alcohol with at least a 70% concentration if soap and 
water are not available 
4. Maintain a safe distance of at least 2 meters from 
others, especially those who are coughing and 
sneezing.  
5. Avoid public places as much as possible, especially 
those that do not allow to maintain a safe distance 
such as traditional markets, public transportation, 
and others. 
6. Avoid close contact with people who are sick with 
any disease, especially those who are undergoing 
treatment at the hospital (Omer et al., 2020). 
Elderly aged over 65 years must fully avoid traveling 
outside the house because of a higher risk of infection. 
This is related to the immune system that has begun to 
decline, so it is necessary to take more intensive 
precautions to avoid being infected with COVID-19. In 
general, the principles of prevention of transmission of 
COVID-19 are stated by WHO as physical distancing, 
which is as much as possible to keep a safe distance from 
others (Djalante et al., 2020). 
Mode of transmission COVID-19 
In general, a typical symptom of COVID-19 is a 
respiratory infection that is transmitted through 
respiratory droplets. The SARS-CoV-2 can spread 
between people who are close by through respiratory 
droplets or direct contact routes that were previously in 
contact with droplets (Peng et al., 2020). Transmission 
from a droplet when someone makes close contact 
within a distance of 1 meter or less with someone who 
coughs or sneezes can be inhaled directly through the 
nose or mouth, especially if the person is not wearing a 
mask or face shield (Guner et al., 2020). Therefore, in 
addition to maintaining a safe distance, protecting the 
mouth, nose, and eyes from possible exposure to 
respiratory droplets is also mandatory, especially in areas 
known to have positive cases of COVID-19 (Liu et al., 
2020a). In addition to being transmitted directly through 
droplets, a person can also be infected if it touches the 
surface of an object that has been exposed to droplets 
containing SARS-CoV-2 for some time. SARS-CoV-2 
itself is known to have a long lifetime on several surfaces 
of the object, so washing hands becomes mandatory after 
touching the surface of any object. Also, you can use 
waterproof gloves when on the move and take it off 
when it touches the face (Morawska & Cao, 2020). The 
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incubation period for COVID-19 itself varies between 
individuals, with an average of five to six days and can be 
as long as 14 days (Lauer et al., 2020). 
 
DRUGS AND VACCINES ON 
TREATMENT OF COVID-19 
Chloroquine 
Chloroquine is a quinoline compound that has a 
structure similar to quinine, an alkaloid compound 
found in the Chinchona sp. plant, and used as an 
antimalarial drug. The US uses chloroquine as one of the 
treatment options for COVID-19. Its use has been 
approved by the FDA to be tested as a treatment for 
COVID-19. Chloroquine is being tested in various clinical 
trials conducted by government agencies and academic 
institutions. Chloroquine is known to inhibit viral 
infections by increasing the endosomal pH needed for 
viral/cell fusion, inhibiting entry through changes in 
glycosylation of ACE2 receptors and spike proteins 
(Megarbane, 2020; Wang et al., 2020d). 
Hydroxychloroquine 
Hydroxychloroquine is a hydroxy derivative of 
chloroquine which has antimalarial activity such as 
chloroquine but with fewer side effects. Like chloroquine, 
hydroxychloroquine inhibits entry of SARS-CoV-2 
through changing the glycosylation of receptors-ACE2 
and spike protein viruses (Gautret et al., 2020; Liu et al., 
2020b). 
Teicoplanin 
Teicoplanin is an antibiotic (glycopeptide) marketed by 
Sanofi-Aventis routinely used to treatment of bacterial 
infection. it was found to be active in vitro against SARS-
CoV, has joined the list of molecules that could be used as 
4 therapeutic arsenals against COVID-19. According to 
the current study showed that this activity was 
conserved on SARS-CoV-2 (the target sequence that 
serves as the cleavage site for cathepsin L is conserved 
among SARS-CoV spike protein). Based on data of 
teicoplanin usage in the treatment of infectious diseases, 
with further newly investigation of the antiviral effect of 
this molecule on SARS-CoV-2 and suggest teicoplanin as 
another potential alternative for the treatment of COVID-
19. Teicoplanin works by inhibiting cell wall synthesis 
(Baron et al., 2020). 
Remdesivir  
Remdesivir is a broad-spectrum antiviral medication 
developed by the biopharmaceutical company Gilead 
Sciences and now being tested in two phases III 
randomized clinical trials in Asian countries against the 
COVID-19. The trials are performing on 750 and more 
patients in a randomized at multiple hospitals in Wuhan, 
the epicenter of the novel coronavirus outbreak. The 
results from the trials are expected to be coming maybe 
in a few weeks. According to a report by remdesivir, 
when administered to a coronavirus patient in the US, 
appeared to have improved the clinical condition of 
patients (Wang et al., 2020c; Norrie, 2020). 
Favilavir 
Favilavir is an antiviral medication used to treat influenza 
in Japan, being developed and manufactured by Toyama 
Chemical and used as a treatment for coronavirus in 
Japan. Favilavir or favipiravir was formerly called 
fapilavir. The drug has reportedly shown efficacy in 
treating the disease with minimum side effects in a 
clinical trial with 70 patients. The clinical trial is being 
conducted in Shenzhen, Guangdong province (Zhai et al., 
2020). 
Lopinavir-ritonavir 
The combination of lopinavir and ritonavir (also known 
as Kaletra) developed by AbbVie, Inc. was originally 
designed to treat HIV. In the clinical trial, the patient was 
54 years old and was given a combination of these two 
drugs and had a significant source of reduction in his 
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SARS-CoV-2 levels (Guo et al., 2020). However, a recent 
report by Cao et al. (2020) mentioned that in hospitalized 
adult patients with severe COVID-19, no benefit was 
observed with lopinavir-ritonavir treatment beyond 
standard care. 
Gimsilumab 
Gimsilumab (formerly known as MORAb 022) 
developed by Roivant Sciences is a fully human 
monoclonal antibody that acts on the granulocyte-
macrophage colony-stimulating factor (GM-CSF). The 
drug makes targets on GM-CSF, which is a pro-
inflammatory cytokine found in high levels in the serum 
of COVID-19 patients. Targeting on GM-CSF is realize to 
reduce lung damage and reduce the mortality rate in 
COVID-19 patients (Tay et al., 2020). 
Fusogenix DNA vaccine 
The Fusogenix DNA vaccine was developed by Entos 
Pharmaceuticals using a fusogenix drug administration 
platform to treat COVID-19 infections. The Fusogenix 
DNA drug delivery platform is a proteo-lipid vehicle that 
introduces genetics directly into cells. Fusogenix DNA in 
the development of additional load containing several 
epitope proteins derived from several SARS-COV-2 
proteins, which will stimulate the immune response in 
the body to prevent and control COVID-19 infections (El-
Aziz & Stockand, 2020). 
ChAdOx1 nCoV-19 vaccine 
ChAdOx1 nCoV-19 is an adenovirus vaccine vector 
developed by the University of Oxford which is a 
weakened version of a common cold virus (adenovirus) 
that causes infections in chimpanzees, that has been 
genetically changed so that it cannot replicate in humans. 
The vaccine in a clinical trial planned for treatment for 
COVID-19. Approximately 510 Patients aged between 18 
to 55 years will be registered for the study (Doremalen et 
al., 2020). 
AdCOVID 
AdCOVID is a single-dose, intranasal vaccine candidate 
designed to protect against COVID-19, developed by 
Altimmune, Inc. in collaboration with the University of 
Alabama at Birmingham. It currently carrying out 
immunogenicity studies after, which phase one clinical-
trial material, will be developed. Scientists conducted 
pre-clinical animal studies and phases one clinical-trial in 
the third quarter of 2020 (World Health Organization, 
2020). 
TJM2 
TJM2 is a monoclonal antibody designed to neutralize 
GM-CSF which is responsible for acute and chronic 
inflammation and developed by I-Mab Biopharma. It is a 
treatment for cytokine storm in patients suffering from a 
severe condition of novel coronavirus infection. This 
TJM2 may be used for treating COVID-19 and still 
undergoing preclinical and clinical trials. One-arm 
clinical trials, open-label trials will assess the ability of 
TJM2 in reducing cytokine levels, including GM-CSF, in 
people with severe SARS-CoV-2 infection in South Korea 
(Pawar, 2020). 
AT-100 
AT-100 is a new recombinant human protein rhSP-D (an 
engineered version of endogenous protein) that reduces 
inflammation and infection while modulating the 
immune response to break the cycle of injury and 
inflammation. AT-100 was developed by Airway 
Therapeutics, Inc. as a treatment for COVID-19. AT-100 
has shown efficacy in pre-clinical studies in reducing 
inflammation and infection in the lungs, while also 
generating multiple immune responses against various 
respiratory diseases (Sandra, 2020). 
TZLS-501 
TZLS-501 is a monoclonal antibody for the treatment of 
Novel Coronavirus developed by Tiziana Life Sciences. 
This monoclonal antibody is a human IL-6R (anti-
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interleukin-6 receptor). TZLS-501 prevents lung damage 
and increases IL-6 levels. This drug works by binding to 
IL-6R and depleting the amount of IL-6 that circulates in 
the body, thereby inhibiting chronic lung inflammation 
(Tiziana Life Sciences, 2020; Duddu, 2020). 
OYA1 
OYA1 is an antiviral compound developed by OyaGen, 
Inc. and has strong antiviral activity against coronavirus 
in the laboratory-based assays against the coronaviruses 
SARS-CoV-2 and MERS-CoV and also is a dual target-
specific antiviral against filoviruses such as Ebola virus. It 
was found to be more effective in inhibiting SARS-CoV-
2 from replication in cell culture. OYA1 is planned to be 
further investigated to determine the efficacy of treating 
coronavirus (Pawar, 2020). 
BPI-002 
BPI-002 by BeyondSpring, Inc. is a novel orally 
administered small molecule agent that is a potent T-cell 
co-stimulator. BPI-002 is indicated for treating different 
infections including COVID-19. It can activate CD4+ 
helper T cells and CD8+ cytotoxic T cells generating an 
immune response to the body. It gives a better response 
if combined with another COVID-19 vaccine and can 
generate long-term protection against viral infections 
(BeyondSpring, 2020; Duddu, 2020). 
NP-120 
NP-120 or Ifenprodil by Algernon Pharmaceuticals is a 
small molecule given orally, originally developed by 
Sanofi to treat disorders of peripheral circulation. NP-120 
is also a potential treatment for COVID-19. NP-120 is an 
N-methyl-d-aspartate (NDMA) glutamate receptor 
antagonist specifically targeting NMDA-type 2B 
(Glu2NB) subunits. NP-120 also shows agonist activity 
for the Sigma-1 receptor, a companion protein that is 
regulated during endoplasmic reticulum stress 
(Algernon Pharmaceuticals, 2020; Duddu, 2020). 
APN01 
APN01 is a recombinant form of human angiotensin-
converting enzyme 2 (ACE2) that has previously been 
tested in phase 1 and 2 trials for acute lung injury (ALI) 
and pulmonary artery hypertension (PAH) involving 89 
patients. APB01 was developed by the University of 
British Columbia and APEIRON Biologics is being tested 
in China in a phase 1 pilot trial as a treatment for COVID-
19. APN01 is on researching for treating SARS. The 
research that the ACE2 protein was the main receptor for 
the SARS virus. The clinical trial will test the drug's 
efficacy in reducing the viral load in patients (APEIRON 
Biologics, 2020; Duddu, 2020). 
mRNA-1273 
mRNA-1273 developed by Moderna and Vaccine 
Research Center is a novel lipid nanoparticle (LNP)-
encapsulated mRNA-based vaccine that encodes for a 
full-length, prefusion stabilized spike (S) protein of 
SARS-CoV-2. Enrollment will occur at up to 3 domestic 
clinical research sites. The vaccine has been 
manufactured for phases I human clinical trial. The trial 
began in mid-March at the Washington Health Research 
Institute in Seattle, Washington. A total volunteer of 45 
males and females aged between 18 and 45 have been 
enrolled for the clinical trial. The volunteer will be 
divided into three cohorts who will be administered 25 
µg, 100 µg, or 250 µg dose 28 days apart (Moderna, 2020). 
TNX-1800 
TNX-1800 is a modified horsepox virus and is designed 
to express proteins from SARS-CoV-2. TNX-1800 was 
developed by Tonix Pharmaceuticals in a strategic 
collaboration with Southern Research. It is believed that 
horsepox has the potential to be a vector for vaccines to 
protect against other infectious agents. The new research 
collaboration will develop and test a potential horsepox 
vaccine that expresses protein from SARS-CoV-2 to 
protect against COVID-19 (Tonix Pharmaceuticals, 2020). 
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Brilacidin 
Brilacidin (PMX30063) is a polymer-based antibiotic 
currently in human clinical trials and represents a new 
class of antibiotics called host defense protein mimetics, 
or HDP-mimetics, which are non-peptide synthetic small 
molecules modeled after host defense peptides (HDPs) 
(Mensa et al., 2014). Brilacidin is currently developed by 
Innovation Pharmaceuticals and shown anti-
inflammatory, antibacterial, and immunomodulatory 
properties in several clinical trials. These drugs for 
inflammatory bowel disease and oral mucositis in cancer 
patients. Innovation Pharmaceutical has signed two 
material transfer agreements with a university and 12 
biocontainment laboratories in the US to evaluate 
brilacidin as COVID-19 therapy (Innovation 
Pharmaceuticals, 2020; Duddu, 2020). 
BXT-25 
BXT-25 is an anti-necrosis drug that carries oxygen to 
tissues when the flow of blood is blocked. BXT-25 has 
been developed by Bioxytran, Inc. as a treatment for 
Acute Respiratory Distress Syndrome (ARDS) in late-
stage patients infected with the SARS-CoV-2. The drug 
may help in transport oxygen to the vital organs and 
enable the patient to recover and survive. The treatment 
will allegedly offer enough time for the patient to recover 
and, over time, the body’s immune system will destroy 
the virus (Bioxytran, 2020; Duddu, 2020). 
Galidesivir 
Galidesivir by Biocryst Pharmaceuticals, Inc is an 
antiviral drug, an adenosine analog, and broad-spectrum 
antiviral in advanced development for the treatment of 
viruses that pose a threat to health and national security, 
including SARS-CoV-2. Tests show that galidesivir is safe 
and generally well-tolerated through evidence in clinical 
phase 1 safety and pharmacokinetic trials by the route of 
intravenous and intramuscular administration in healthy 
subjects. In studies using test animals, galidesivir shows 
survival benefits against a variety of serious pathogens 
(Biocryst Pharmaceuticals, 2020). 
REGN3048-3051 
REGN3051 and REGN3048 developed by Regeneron 
Pharmaceuticals are two human monoclonal antibodies 
that neutralize MERS-CoV by reducing viral replication 
in mice expressing human DPP4 based on prophylactic 
and therapeutic treatment (de Wit et al., 2018). REGN3048 
and REGN3051 are being studied for their activity 
against coronavirus infections in the first clinical trials in 
humans sponsored by the National Institute of Allergy 
and Infectious Diseases (NIAID). Clinical trials of this 
drug will be studied in 48 patients, in which both 
antibodies bind to the S protein from MERS-CoV 
(Regeneron Pharmaceuticals, 2020; Duddu, 2020). 
Kevzara 
Kevzara or sarilumab developed by Regeneron 
Pharmaceuticals-Sanofi is a fully human monoclonal 
antibody, in phase two leading to three clinical trials in 
patients with severe COVID-19 infection. Kevzara is 
approved for the treatment of rheumatoid arthritis and is 
known to block the interleukin-6 (IL-6) pathway, which 
causes an overactive inflammatory response in the lungs 
of COVID-19 patients (Regeneron Pharmaceuticals, 2020; 
Magro, 2020; Duddu, 2020). 
SNG001 
SNG001 developed by Synairgen Research is the IFN-β-
1a formulation for direct delivery to the lungs through 
nebulization. This is a neutral pH and free of mannitol, 
arginine, albumin, and human serum, making it suitable 
for direct inhalation delivery to the active site. SNG001 
can be proven to have an important role in the current 
outbreak COVID-19 epidemic, especially concerning 
high-risk populations very affected by this virus and the 
like (Synairgen Research, 2020; Mantlo et al., 2020; 
Duddu, 2020). 
Mukim M, Kabra A, Devi S, Chaturvedi M, Patel R. 2020. Global Pandemic and Possible Medications and Vaccines for COVID-19 
97 
TAK-888 
TAK-888 is an anti-SARS-CoV-2 polyclonal 
hyperimmune globulin (H-IG) considered to treat high-
risk individuals which developed by Takeda. TAK-888 
began to enter the development phase of an anti-SARS-
CoV-2 H-IG to treat individuals at maximum risk with 
SARS-CoV-2. Hyperimmune globulin is a plasma 
derivative therapy that has previously been proven 
effective in the treatment of severe acute viral respiratory 
infections and can be the treatment of choice for COVID-
19 patients (Takeda, 2020). 
 
COVID-19 CONFIRMED CASES IN 
WORLDWIDE AND INDIA 
With almost all countries in the world affected by the 
COVID-19 pandemic, some countries show relatively 
more severe conditions than others. While some 
countries choose to do partial or total lockdowns, certain 
countries choose not to impose strict restrictions until 
they do not impose any restrictions. This condition causes 
the spread of COVID-19 in several countries, especially 
those in Europe and America far higher than others. In 
addition to the restriction policy factors adopted by the 
local government, the population of citizens from each 
country also has an influence on the high number of 
COVID-19 cases in several countries. According to the 
Worldometer (2020), a database that reports the detailed 
information and increase in COVID-19 confirmed cases 
in all countries in the world in detail and is updated daily, 
these countries have the highest number of COVID-19 
cases, as presented in Table II. The interesting thing is 
that of the 10 countries, only Iran is in Asia, which 
incidentally is the continent where the COVID-19 case 
was first discovered. These points reinforce that the 
COVID-19 epicenter is currently on the continents of 
Europe and America. 
Table II. The number of COVID-19 confirmed cases 
worldwide per May 11th, 2020 (Worldometer, 2020) 
No Country name 
Confirmed 
cases 
Death 
1 USA 1,271,645 76,916 
2 Spain 224,390 26,621 
3 Russian Federation  221,344 2,009 
4 United Kingdom 219,187 31,855 
5 Italy 219,070 30,560 
6 Germany 169,575 7,417 
7 Brazil  155,939 10,627 
8 Turkey  138,657 3,786 
9 France 137,073 26,338 
10 Iran 107,603 6,640 
 
On the other hand, India as one of the countries with the 
second most populous population in the world after 
China, when this article was written was indeed not 
included in the top 10 countries with the highest number 
of COVID-19 cases. One of the reasons is the Indian 
government's policy which immediately implemented a 
total lockdown when the number of COVID-10 
confirmed cases in India began to increase sharply. 
However, seeing a large number of population in India 
and the trend of the increasing number of confirmed 
cases quickly, it is not impossible the number of COVID-
19 cases in India can increase rapidly in the next few 
weeks. Still based on the Worldometer (2020), the 
number of COVID-19 confirmed cases in each state 
throughout India is presented in Table III. As of May 
11th, 2020, the highest number of cases were reported in 
the state of Maharashtra, with the number of cases nearly 
three times more than Gujarat as the state with the 
second-most cases. 
Table III. The number of COVID-19 confirmed cases in India 
per May 11th, 2020 (Worldometer, 2020) 
No 
Name of States/ 
Union territories 
Confirmed 
cases 
Death 
1 Maharashtra 22,171 832 
2 Gujarat 8,194 493 
3 Tamil Nadu 7,204 47 
4 Delhi 6,923 73 
5 Rajasthan 3,814 107 
6 Madhya Pradesh 3,614 215 
7 Uttar Pradesh 3,467 74 
8 Andhra Pradesh 1,980 45 
9 West Bengal 1,939 185 
10 Punjab 1,823 31 
11 Telangana 1,196 30 
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12 Jammu and Kashmir 861 9 
13 Karnataka 848 31 
14 Haryana 703 10 
15 Bihar 696 6 
16 Kerala 512 4 
17 Odisha 377 3 
18 Chandigarh 169 2 
19 Jharkhand 158 3 
20 Tripura 150 0 
21 Uttarakhand 68 1 
22 Assam 63 2 
23 Chhattisgarh 59 0 
24 Himachal Pradesh 55 2 
25 Ladakh 42 0 
26 Andaman & Nicobar 
Islands 
33 0 
27 Meghalaya 13 1 
28 Puducherry 9 0 
29 Goa 7 0 
30 Manipur 2 0 
31 Arunachal Pradesh 1 0 
32 Nagaland 1 0 
33 Mizoram 1 0 
Total  number of confirmed 
cases in India 
67,152 2,206 
 
 
TESTING CENTERS FOR COVID-19 IN 
INDIA 
As of May 6th, 2020, there were only 445 laboratories both 
government and private throughout India that served 
COVID-19 examinations, as reported by the Indian 
Council of Medical Research (2020). The number is 
certainly relatively small compared to the area of India 
and the large population. However, the increase in the 
number of laboratories is quite fast, where on May 3rd, 
2020 there were only 426 laboratories reported or 
experienced an increase in 19 laboratories over three 
days. Overall, the number of testing centers for COVID-
19 throughout India is presented in Table IV. 
Table IV. The number of testing centers for COVID-19 in 
India per May 6th, 2020 (Indian Council of Medical 
Research, 2020) 
No 
Name of States/ 
Union territories 
Number of testing 
centers for COVID-19 
1 Andhra Pradesh 48 
2 Arunachal Pradesh 1 
3 Assam 7 
4 Bihar 7 
5 Chandigarh 3 
6 Chhattisgarh 5 
7 Delhi 26 
8 Gujarat 24 
9 Goa 3 
10 Haryana 18 
11 Himachal Pradesh 5 
12 Jammu & Kashmir 5 
13 Jharkhand 5 
14 Karnataka 30 
15 Kerala 20 
16 Maharashtra 58 
17 Madhya Pradesh 13 
18 Manipur 2 
19 Meghalaya 1 
20 Mizoram 1 
21 Nagaland 2 
22 Odisha 8 
23 Puducherry 2 
24 Punjab 6 
25 Rajasthan 20 
26 Tamil Nadu 52 
27 Telangana 20 
28 Tripura 1 
29 Uttar Pradesh 24 
30 Uttarakhand 5 
31 West Bengal 18 
32 Andaman & Nicobar 
Islands 
3 
33 Dadra & Nagar Haveli 1 
34 Sikkim 1 
 
 
CONCLUSION 
Despite its rapid spread and its deadly effect on some 
people, COVID-19 still holds the chance to be conquered 
through the discovery and repurposing of various drug 
compounds and vaccines. Today the whole world 
depends entirely on the speed of various laboratories, 
universities, and the pharmaceutical industry in finding 
and testing drug compounds that can be relied upon for 
COVID-19 therapy. Despite the progress that has been 
made, advances in clinical trials of some drugs such as 
remdesivir may raise hopes that the discovery of 
therapies for COVID-19 can be made this year. 
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